DK0616808T3 - Anvendelse af rifaximin og farmeaceutiske præparater indeholdende rifaximin til behandling af gastri sk dyspepsi forårsaget af Heliobacter pylori - Google Patents

Anvendelse af rifaximin og farmeaceutiske præparater indeholdende rifaximin til behandling af gastri sk dyspepsi forårsaget af Heliobacter pylori

Info

Publication number
DK0616808T3
DK0616808T3 DK94104308.5T DK94104308T DK0616808T3 DK 0616808 T3 DK0616808 T3 DK 0616808T3 DK 94104308 T DK94104308 T DK 94104308T DK 0616808 T3 DK0616808 T3 DK 0616808T3
Authority
DK
Denmark
Prior art keywords
rifaximin
treatment
pharmaceuticals containing
heliobacter pylori
dyspepsia caused
Prior art date
Application number
DK94104308.5T
Other languages
English (en)
Inventor
Antonella Ferrieri
Leone Gabriele Rotini
Original Assignee
Alfa Wassermann Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wassermann Spa filed Critical Alfa Wassermann Spa
Application granted granted Critical
Publication of DK0616808T3 publication Critical patent/DK0616808T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DK94104308.5T 1993-03-23 1994-03-18 Anvendelse af rifaximin og farmeaceutiske præparater indeholdende rifaximin til behandling af gastri sk dyspepsi forårsaget af Heliobacter pylori DK0616808T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT93BO000099A IT1264494B1 (it) 1993-03-23 1993-03-23 Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter

Publications (1)

Publication Number Publication Date
DK0616808T3 true DK0616808T3 (da) 1996-09-30

Family

ID=11338806

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94104308.5T DK0616808T3 (da) 1993-03-23 1994-03-18 Anvendelse af rifaximin og farmeaceutiske præparater indeholdende rifaximin til behandling af gastri sk dyspepsi forårsaget af Heliobacter pylori

Country Status (11)

Country Link
US (1) US5352679A (da)
EP (1) EP0616808B1 (da)
JP (1) JP2755550B2 (da)
KR (1) KR0177846B1 (da)
AT (1) ATE142495T1 (da)
CA (1) CA2115381C (da)
DE (1) DE69400493T2 (da)
DK (1) DK0616808T3 (da)
ES (1) ES2091649T3 (da)
GR (1) GR3020984T3 (da)
IT (1) IT1264494B1 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5834002A (en) 1994-05-02 1998-11-10 Josman Laboratories, Inc. Chewing gum containing colloidal bismuth subcitrate
US6902738B2 (en) * 1994-05-02 2005-06-07 Josman Laboratories, Inc. Topical oral dosage forms containing bismuth compounds
US6426085B1 (en) 1994-05-02 2002-07-30 Josman Laboratories Inc. Use of bismuth-containing compounds in topical oral dosage forms for the treatment of halitosis
AU4596796A (en) * 1995-02-07 1996-08-27 Narayan Krishnarao Athanikar Concomitant treatment with bismuth and antibacterials
US6379651B1 (en) 1995-02-07 2002-04-30 Josman Laboratories Oral-topical dosage forms for delivering antibacterials/antibiotics to oral cavity to eradicate H. pylori as a concomitant treatment for peptic ulcers and other gastro-intestinal diseases
US6372784B1 (en) 1995-02-07 2002-04-16 Josman Laboratories, Inc. Bismuth-containing compounds in topical dosage forms for treatment of corneal and dermal wounds
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US6861053B1 (en) * 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US5981522A (en) * 1995-09-01 1999-11-09 Kaneka Corporation Treatment of disease caused by infection of Helicobacter
IT1290679B1 (it) * 1997-02-14 1998-12-10 Alfa Wassermann Spa Uso della rifaximina e delle composizioni farmaceutiche che la contengono nel trattamento della diarrea da criptosporidiosi.
ES2237809T3 (es) * 1997-02-28 2005-08-01 Kaneka Corporation Medicina curativa para la enfermedad causada por infeccion de helicobacter.
US7122525B2 (en) * 2001-11-21 2006-10-17 Activbiotics, Inc. Targeted therapeutics and uses thereof
US7078399B2 (en) * 2001-12-13 2006-07-18 Activbiotics, Inc. Sulfhydryl rifamycins and uses thereof
US7820652B2 (en) * 2003-09-24 2010-10-26 Activbiotics Pharma, Llc Regimen for the administration of rifamycin-class antibiotics
US20060210483A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Non-systemic antibiotic formulations and related method of use and treatment of upper respiratory infections
US20060210492A1 (en) * 2005-03-02 2006-09-21 Kodsi Robert E Use of rifaximin for treatment and prevention of periodontal conditions
US8003118B2 (en) * 2005-03-02 2011-08-23 Kodsi Robert E Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis
PT1698630E (pt) 2005-03-03 2014-09-15 Alfa Wassermann Spa Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
ITMI20061692A1 (it) 2006-09-05 2008-03-06 Alfa Wassermann Spa Uso di polioli per ottenere forme polimorfe stabili di rifaximina
US20080161337A1 (en) * 2007-01-03 2008-07-03 Leonard Weinstock Use of Rifaximin for the Treatment of Chronic Prostatitis
ES2798253T3 (es) † 2007-07-06 2020-12-10 Lupin Ltd Composiciones farmacéuticas de rifaximina
AU2009297562B2 (en) 2008-09-26 2015-04-23 Alfasigma S.P.A. Agent for preventing and/or treating functional gastrointestinal disorder
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
US12285414B2 (en) 2008-10-02 2025-04-29 Salix Pharmaceuticals, Inc. Methods of treating hepatic encephalopathy
WO2010044093A1 (en) * 2008-10-16 2010-04-22 Strides Arcolab Limited Formulations containing rifaximin
BR112012012315A2 (pt) 2009-11-23 2018-10-16 Cipla Ltd composição farmacêutica para administração retal tópica na forma de espuma, uso de uma composição farmacêutica, método para tratamento, prevenção ou alívio de um dustúrbio no reto, cólon, íleo terminal ou anus, processo para fabricação de uma composição farmacêutica contendo rifaximina, uso de silicone e dispensador para composição farmacêutica
EP2503989A2 (en) 2009-11-23 2012-10-03 Cipla Limited Topical foam composition
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN103221032A (zh) 2010-09-13 2013-07-24 西普拉有限公司 药物组合物
WO2012076832A1 (en) 2010-12-09 2012-06-14 Cipla Limited Suppositories comprising rifaximin
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
EP2927235B1 (en) 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
AU2015260837B2 (en) 2014-05-12 2019-02-28 Alfasigma S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
MX381919B (es) * 2014-06-30 2025-03-13 Salix Pharmaceuticals Inc Métodos para repetir tratamiento de síndrome del intestino irritable (ibs).
ES2979135T3 (es) 2016-10-14 2024-09-24 Cipla Ltd Composiciones farmacéuticas que comprenden rifaximina
MX427410B (es) 2019-09-24 2025-10-13 Bausch Health Ireland Ltd Formulaciones liquidas de rifaximina

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) * 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica

Also Published As

Publication number Publication date
DE69400493D1 (de) 1996-10-17
CA2115381A1 (en) 1994-09-24
EP0616808A1 (en) 1994-09-28
CA2115381C (en) 1999-01-05
EP0616808B1 (en) 1996-09-11
GR3020984T3 (en) 1996-12-31
JPH06298768A (ja) 1994-10-25
ES2091649T3 (es) 1996-11-01
ATE142495T1 (de) 1996-09-15
US5352679A (en) 1994-10-04
IT1264494B1 (it) 1996-09-24
KR0177846B1 (ko) 1999-03-20
ITBO930099A0 (it) 1993-03-23
ITBO930099A1 (it) 1994-09-23
DE69400493T2 (de) 1997-01-23
JP2755550B2 (ja) 1998-05-20

Similar Documents

Publication Publication Date Title
GR3020984T3 (en) Use of rifaximin and pharmaceutical compositions containing it in the treatment of gastric dyspepsia caused by helicobacter pylori.
WO2004032909A3 (en) Stabilized pharmaceutical composition containing basic excipients
IL120382A (en) Extended release formulation of venlafaxine hydrochloride
DE59707812D1 (de) Opioidantagonisthaltige galenische formulierung
PL304389A1 (en) Pharmaceutical composition for controllable release
CA2108455A1 (en) Pharmaceutical compositions against gastric disorders
WO2004043430A3 (en) Botulinum toxin formulations for oral administration
NO20053104D0 (no) Oral, analgesisk doseringsform med forlenget frigivelse for administrering ±n gang pr. dag.
DK0612248T3 (da) Præparat, der indeholder cisplatin og topotecan som antitumormiddel
WO1999030693A3 (en) A double capsule for the administration of active principles in multiple therapies
DK0530087T3 (da) Hidtil ukendte naphthylethylurinstof- og naphthylethylthiourinstofforbindelser, fremgangsmåde til fremstilling heraf og farmaceutiske midler, som indeholder dem
AU6945491A (en) Pimobendan compositions
PT1411921E (pt) Composições farmacêuticas contendo terbinafina e suas utilizações
NO304113B1 (no) Krystallinsk tiagabinhydrokloridmonohydrat, farmas°ytisk preparat som omfatter det, og anvendelse derav for fremstilling av et medikament
DE69927584D1 (de) Pharmazeutische zubereitungen zur behandlung von magengeschwüren
TR199800421A2 (xx) Moenomisin grubu antibiyotiklerin bizmut tuzlar�.
DK0655249T3 (da) Moenomycin som lægemiddel til behandling af mavesår
EP0515995A3 (en) N-(5-thioxo-l-prolyl)-l-cysteine, derivatives thereof, processes for the preparation thereof and pharmaceutical compositions containing them
SG40063A1 (en) Concomitant treatment with oral-topical dosage forms of bismuth compounds antibacterials/antibiotics to eradicate H.pylori from the oral cavity in combination
CA2136801A1 (en) Pharmaceutical Agents for the Treatment of Disorders Caused by Helicobacter Pylori or Other Spiral Urease-Positive Gram-Negative Bacteria
GEP20043377B (en) Pharmaceutical Complex
RU2003133155A (ru) Способ эрадикации инфекции helicobacter pylori в желудке
FI952765A0 (fi) Desogestreeliä sisältävä tabletti, kapseli tai rae
DE59501945D1 (de) Orale Arzeimittelzubereitung enthaltend Diclofenac-Natrium und eine organische Säure
AU1240800A (en) Granular, free-flowing pharmaceutical composition, and straw-like dosage form for oral administration thereof